NOVAVAX INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
NOVAVAX INC (NVAX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 0.50% for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2021-05-10
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2021-03-31 was 0.50%, a 16.67% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2020-03-31 was 0.60%, a 75.00% decline year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2019-03-31 was 2.40%, a 6.19% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for the quarter ending 2018-09-30 was 2.68%, a 66.46% increase year-over-year.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2018 was 2.26%, a 40.37% increase from fiscal 2017.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2017 was 1.61%, a 65.98% increase from fiscal 2016.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2016 was 0.97%, a 18.49% decline from fiscal 2015.
- NOVAVAX INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2015 was 1.19%, a 4.03% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|---|---|---|
| 2021-03-31 | 0.50% 10-Q · filed 2021-05-10 | |||
| 2020-03-31 | 0.60% 10-Q · filed 2021-05-10 | |||
| 2019-03-31 | 2.40% 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | 2.26% 10-K · filed 2019-03-18 | |||
| 2018-09-30 | 2.68% 10-Q · filed 2018-11-07 | 2.26% 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | 2.59% 10-Q · filed 2018-08-08 | 2.26% 10-Q · filed 2018-08-08 | ||
| 2018-03-31 | 2.26% 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | 1.61% 10-K · filed 2019-03-18 | |||
| 2017-09-30 | 1.61% 10-Q · filed 2018-11-07 | 1.61% 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | 1.63% 10-Q · filed 2018-08-08 | 1.63% 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | 1.73% 10-Q · filed 2018-05-09 | |||
| 2016-12-31 | 0.97% 10-K · filed 2019-03-18 | |||
| 2016-09-30 | 0.97% 10-Q · filed 2017-11-07 | 0.97% 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | 1.07% 10-Q · filed 2017-08-08 | 1.07% 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | 1.25% 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | 1.19% 10-K · filed 2018-03-14 | |||
| 2015-09-30 | 1.32% 10-Q · filed 2016-11-09 | 1.19% 10-Q · filed 2016-11-09 | ||
| 2015-06-30 | 1.37% 10-Q · filed 2016-08-09 | 1.19% 10-Q · filed 2016-08-09 | ||
| 2014-12-31 | 1.24% 10-K · filed 2017-02-27 | |||
| 2014-09-30 | 1.43% 10-Q · filed 2015-11-09 | 1.24% 10-Q · filed 2015-11-09 | ||
| 2014-06-30 | 1.33% 10-Q · filed 2015-08-10 | 1.24% 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | 1.24% 10-Q · filed 2015-05-07 | |||
| 2013-12-31 | 0.54% 10-K · filed 2016-02-29 | |||
| 2013-09-30 | 1.12% 10-Q · filed 2014-11-06 | 0.54% 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | 0.54% 10-Q · filed 2014-08-07 | 0.54% 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | 0.62% 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | 0.55% 10-K · filed 2015-02-27 | |||
| 2012-09-30 | 0.55% 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | 0.59% 10-Q · filed 2012-08-09 | 0.59% 10-Q · filed 2013-08-08 | ||
| 2012-03-31 | 0.82% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 0.48% 10-K · filed 2014-03-12 | |||
| 2011-09-30 | 0.48% 10-Q · filed 2012-11-09 | 0.48% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 0.83% 10-Q · filed 2012-08-09 | 0.83% 10-Q · filed 2012-08-09 | ||
| 2010-12-31 | 0.93% 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |